氧气驱动雾化吸入用复方异丙托溴铵溶液防治支气管哮喘急性发作的临床观察(1)
【摘要】 目的 探討氧气驱动雾化吸入用复方异丙托溴铵溶液治疗支气管哮喘急性发作期的临床治疗效果。方法 50例支气管哮喘急性发作期患者， 随机分为治疗组(26例)和对照组(24例)。对照组患者采用解痉、平喘、抗炎等对症治疗， 治疗组患者在对照组基础上给予氧气驱动雾化吸入用复方异丙托溴铵溶液治疗， 比较两组患者治疗前及治疗3 d后桡动脉血中血氧分压(PaO2)、二氧化碳分压(PaCO2)指标以及静脉血中白三烯B4(LTB4)的含量。结果 治疗组总有效率为96%， 明显高于对照组的67%， 差异有统计学意义(P<0.05)。治疗后， 两组患者PaCO2平均值均低于治疗前， PaO2平均值均高于治疗前， 且治疗组PaCO2、PaO2平均值均优于对照组， 差异有统计学意义(P<0.05)。治疗后， 两组LTB4含量均低于治疗前， 且治疗组低于对照组， 差异有统计学意义(P<0.05)。治疗组有3例出现腹痛、腹泻、恶心、呕吐等症状， 不良反应发生率为 11.5%(3/26)， 对照组也有3例出现恶心呕吐、腹痛、腹泻等症状， 不良反应发生率为12.5%(3/24)；治疗组不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论 氧气驱动雾化吸入用复方异丙托溴铵溶液用于支气管哮喘急性发作期的治疗， 不仅显著缓解了患者的症状， 而且提高了患者的康复、生存质量， 值得广大临床医生借鉴、应用、推广。
【关键词】 支气管哮喘；吸入用复方异丙托溴铵溶液；氧气驱动；雾化；血氧分压；二氧化碳分压；白三烯B4
DOI：10.14163/j.cnki.11-5547/r.2017.09.050
Clinical observation on oxygen-driven atomizing inhalation of compound ipratropium bromide solution in prevention of bronchial asthma acute attack SONG Wei-rong， ZHAO Hua. Shenyang Medical College Affiliated Second Hospital， Shenyang 110002， China
【Abstract】 Objective To explore the clinical treatment effect of oxygen-driven atomizing inhalation of compound ipratropium bromide solution in prevention of bronchial asthma acute attack. Methods A total of 50 bronchial asthma of acute attack stage patients were randomly divided into treatment group (26 cases) and control group (24 cases). The control group received symptomatic treatment of spasmolysis， relieving asthma and anti-inflammatory， and the treatment group received oxygen-driven atomizing inhalation of compound ipratropium bromide solution for treatment on the basis of the control group. Comparison were made on radial artery blood of partial pressure of blood oxygen (PaO2)， partial pressure of carbon dioxide (PaCO2) index and venous blood of leukotriene B4 (LTB4) content before treatment and after 3 d of treatment in two groups. Results The treatment group had obviously higher total effective rate as 96% than 67% in the control group， and the difference had statistical significance (P<0.05). After treatment， both groups had lower mean PaCO2 than before treatment and higher mean PaO2 than before treatment， and the treatment group had better mean PaCO2 and PaO2 than control group. Their difference had statistical significance (P<0.05). After treatment， both groups had lower LTB4 content than before treatment， and the treatment group was lower than the control group. Their difference had statistical significance (P<0.05). The treatment group had 3 patients with symptoms of stomachache， diarrhea， nausea and vomiting， with incidence of adverse reactions as 11.5% (3/26)， while the control group also had 3 patients with symptoms of stomachache， diarrhea， nausea and vomiting， with incidence of adverse reactions as 12.5% (3/24). The treatment group had no statistically significant difference in incidence of adverse reactions comparing with the control group (P>0.05). Conclusion For the treatment of bronchial asthma acute attack， oxygen-driven atomizing inhalation of compound ipratropium bromide solution can not only significantly relieve symptoms of patients， but also improve recovery and survival quality of patients. So it is worthy of reference application and promotion for clinical doctors., 百拇医药(宋威蓉 赵华)
【关键词】 支气管哮喘；吸入用复方异丙托溴铵溶液；氧气驱动；雾化；血氧分压；二氧化碳分压；白三烯B4
DOI：10.14163/j.cnki.11-5547/r.2017.09.050
Clinical observation on oxygen-driven atomizing inhalation of compound ipratropium bromide solution in prevention of bronchial asthma acute attack SONG Wei-rong， ZHAO Hua. Shenyang Medical College Affiliated Second Hospital， Shenyang 110002， China
【Abstract】 Objective To explore the clinical treatment effect of oxygen-driven atomizing inhalation of compound ipratropium bromide solution in prevention of bronchial asthma acute attack. Methods A total of 50 bronchial asthma of acute attack stage patients were randomly divided into treatment group (26 cases) and control group (24 cases). The control group received symptomatic treatment of spasmolysis， relieving asthma and anti-inflammatory， and the treatment group received oxygen-driven atomizing inhalation of compound ipratropium bromide solution for treatment on the basis of the control group. Comparison were made on radial artery blood of partial pressure of blood oxygen (PaO2)， partial pressure of carbon dioxide (PaCO2) index and venous blood of leukotriene B4 (LTB4) content before treatment and after 3 d of treatment in two groups. Results The treatment group had obviously higher total effective rate as 96% than 67% in the control group， and the difference had statistical significance (P<0.05). After treatment， both groups had lower mean PaCO2 than before treatment and higher mean PaO2 than before treatment， and the treatment group had better mean PaCO2 and PaO2 than control group. Their difference had statistical significance (P<0.05). After treatment， both groups had lower LTB4 content than before treatment， and the treatment group was lower than the control group. Their difference had statistical significance (P<0.05). The treatment group had 3 patients with symptoms of stomachache， diarrhea， nausea and vomiting， with incidence of adverse reactions as 11.5% (3/26)， while the control group also had 3 patients with symptoms of stomachache， diarrhea， nausea and vomiting， with incidence of adverse reactions as 12.5% (3/24). The treatment group had no statistically significant difference in incidence of adverse reactions comparing with the control group (P>0.05). Conclusion For the treatment of bronchial asthma acute attack， oxygen-driven atomizing inhalation of compound ipratropium bromide solution can not only significantly relieve symptoms of patients， but also improve recovery and survival quality of patients. So it is worthy of reference application and promotion for clinical doctors., 百拇医药(宋威蓉 赵华)